Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in adult patients with highly active relapsing multiple sclerosis
CADTH
Record ID 32018012109
English
Details
Project Status:
Ongoing
URL for project:
https://www.cadth.ca/alemtuzumab-cladribine-fingolimod-and-natalizumab-first-line-treatments-adult-patients-highly
Anticipated Publish Date:
2024
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Alemtuzumab
- Cladribine
- Fingolimod Hydrochloride
- Natalizumab
- Rituximab
- Antibodies, Monoclonal, Humanized
- Immunosuppressive Agents
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.